Biotech · Private company
Immutep S.A.S.
Track this companyFree. Adds Immutep S.A.S. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- carboplatin plus paclitaxelPhase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- cisplatin or carboplatin + pemetrexedPhase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- eftilagimod alfaPhase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- eftilagimod alphaPhase 3 · Breast CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Breast CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab (KEYTRUDA®)Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- eftilagimod alphaPhase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- eftilagimod alphaPhase 2 · HNSCCClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab (KEYTRUDA®)Phase 2 · HNSCCClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab (KEYTRUDA®)Phase 2 · NSCLCClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 21, 2025ClinicalTrials.gov NCT06726265 · fetched Nov 12, 2026
- Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel ChemotherapyPHASE2_PHASE3 · TERMINATED · started May 22, 2023ClinicalTrials.gov NCT05747794 · fetched Nov 12, 2026
- Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCCPHASE2 · COMPLETED · started Aug 27, 2021ClinicalTrials.gov NCT04811027 · fetched Nov 12, 2026
- Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCPHASE2 · COMPLETED · started Feb 21, 2019ClinicalTrials.gov NCT03625323 · fetched Nov 12, 2026